Filtros de búsqueda

Lista de obras de

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

artículo científico publicado en 2014

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

artículo científico publicado en 2016

A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2017

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

artículo científico publicado en 2006

A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer

artículo científico publicado en 2013

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center

artículo científico publicado en 2017

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

scientific article published on 01 January 2020

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

artículo científico publicado en 2009

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

scientific article published on 01 October 2019

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2013

A phase 2 study of bortezomib in relapsed, refractory myeloma

artículo científico publicado en 2003

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2012

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2015

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

artículo científico publicado en 2008

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2019

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

artículo científico publicado en 2014

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

scientific article published on 01 August 2019

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

artículo científico publicado en 2007

A practical update on the use of bortezomib in the management of multiple myeloma

artículo científico publicado en 2006

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid

artículo científico publicado en 2011

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

artículo científico publicado en 2013

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

artículo científico publicado en 2011

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

artículo científico publicado en 2017

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

artículo científico publicado en 2012

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

artículo científico publicado en 2016

Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

artículo científico publicado en 2020

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient

artículo científico publicado en 2018

Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience

artículo científico publicado en 2017

Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

artículo científico publicado en 2019

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

artículo científico publicado en 2011

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

artículo científico publicado en 2007

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2012

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

artículo científico publicado en 2012

An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma

artículo científico publicado en 2012

Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy

artículo científico publicado en 2015

Antigen-mediated regulation in monoclonal gammopathies and myeloma

artículo científico publicado en 2018

Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.

artículo científico publicado en 2016

Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients

artículo científico publicado en 2015

Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics

artículo científico publicado en 2014

Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma

artículo científico publicado en 2013

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

artículo científico publicado en 2011

Bortezomib and EGCG: no green tea for you?

artículo científico publicado en 2009

Bortezomib and its role in the management of patients with multiple myeloma

artículo científico publicado en 2004

Bortezomib in combination with other therapies for the treatment of multiple myeloma.

artículo científico publicado en 2004

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

artículo científico publicado en 2005

Bortezomib therapy following first relapse.

artículo científico publicado en 2005

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

artículo científico publicado en 2016

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial

scientific article published on 01 December 2018

Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma

artículo científico publicado en 2006

Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM

scientific article published on 01 October 2020

C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.

artículo científico publicado en 2017

CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies

artículo científico publicado en 2012

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

artículo científico publicado en 2015

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia

scientific article published on 19 September 2018

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

artículo científico publicado en 2011

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes

artículo científico publicado en 2017

Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma

artículo científico publicado en 2014

Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells

artículo científico publicado en 2014

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

artículo científico publicado en 2017

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia

artículo científico publicado en 2002

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion

artículo científico publicado en 2017

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

artículo científico publicado en 2013

Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms

artículo científico publicado en 2014

Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression

artículo científico publicado en 2015

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

artículo científico publicado en 2008

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

artículo científico publicado en 2016

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

scientific article published on 22 March 2019

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma ⬇️

artículo científico publicado el 19 de marzo de 2012

Crystal-storing histiocytosis: a clinicopathological study of 13 cases

artículo científico publicado en 2015

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

scientific article published on 23 April 2020

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation

artículo científico publicado en 2022

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

scientific article published on 13 February 2020

Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.

artículo científico publicado en 2002

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

artículo científico publicado en 2018

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

artículo científico publicado en 2016

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

artículo científico publicado en 2012

Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome

artículo científico publicado en 2014

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions

artículo científico publicado en 2014

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

artículo científico publicado en 2012

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial

artículo científico publicado en 2017

Effect of long-term storage in TRIzol on microarray-based gene expression profiling

artículo científico publicado en 2010

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome

artículo científico publicado en 2011

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models

artículo científico publicado en 2015

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

artículo científico publicado en 2014

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

artículo científico publicado en 2020

Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.

artículo científico publicado en 2007

Emerging role of novel combinations for induction therapy in multiple myeloma

artículo científico publicado en 2006

Evidence for involvement of calpain in c-Myc proteolysis in vivo.

artículo científico publicado en 2002

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

artículo científico publicado en 2013

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

artículo científico publicado en 2010

Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma

artículo científico publicado en 2010

Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis

artículo científico publicado en 2002

Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role

artículo científico publicado en 2004

Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

artículo científico publicado en 2009

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

scientific article published on 05 December 2006

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

artículo científico publicado en 2011

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2017

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2016

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2017

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

scientific article published on 05 June 2006

Future agents and treatment directions in multiple myeloma

artículo científico publicado en 2013

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

artículo científico publicado en 2011

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China

artículo científico publicado en 2017

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan

artículo científico publicado en 2017

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

scientific article published on 22 July 2018

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

artículo científico publicado en 2017

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis

artículo científico publicado en 2019

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2018

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

artículo científico publicado en 2013

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

artículo científico publicado en 2011

Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.

artículo científico publicado en 2014

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2018

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

artículo científico publicado en 2007

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737

artículo científico publicado en 2014

Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma

artículo científico publicado en 2008

Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation

artículo científico publicado en 2006

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

artículo científico publicado en 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?

artículo científico publicado en 2006

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

artículo científico

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

artículo científico publicado en 2020

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma

artículo científico publicado en 2018

Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome

artículo científico publicado en 2018

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study

artículo científico publicado en 2015

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous

scientific article published on 11 May 2020

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma

artículo científico publicado en 2014

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

scientific article published on 16 April 2020

Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo

artículo científico publicado en 2010

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation

artículo científico publicado en 2015

Melphalan based autologous transplant in octogenarian multiple myeloma patients

article

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

artículo científico publicado en 2020

Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance

artículo científico publicado en 2007

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

artículo científico publicado en 2013

NF-kappaB as a therapeutic target in cancer

artículo científico publicado en 2002

New Drugs in Multiple Myeloma

artículo científico publicado en 2019

New Paradigm for Radiation in Multiple Myeloma: lower yet effective dose to avoid radiation toxicity

scientific article published on 09 January 2020

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

artículo científico publicado en 2014

Novel Approaches to Treatment of Double-Refractory Multiple Myeloma ⬇️

artículo científico publicado el 1 de enero de 2013

Novel agents for multiple myeloma to overcome resistance in phase III clinical trials

artículo científico publicado en 2013

Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

scientific article published on 28 February 2020

Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia

artículo científico publicado en 2004

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

artículo científico publicado en 2014

Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis

artículo científico publicado en 2019

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

artículo científico publicado en 2015

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2016

Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.

artículo científico publicado en 2017

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

artículo científico publicado en 2016

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation

artículo científico publicado en 2015

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant ⬇️

artículo científico publicado en 2016

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

artículo científico publicado en 2019

Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia

scientific article published on 26 June 2019

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype

artículo científico publicado en 2019

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

artículo científico publicado en 2008

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023.

artículo científico publicado en 2015

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

scientific article published on 15 May 2019

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

artículo científico publicado en 2019

Pembrolizumab in relapsed or refractory Richter syndrome

artículo científico publicado en 2020

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

scientific article published on 01 June 2019

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

artículo científico publicado en 2004

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

artículo científico publicado en 2014

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

artículo científico publicado en 2015

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2017

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

artículo científico publicado en 2002

Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma

scientific article published on 10 May 2020

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

artículo científico publicado en 2015

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma ⬇️

scientific article published on 14 August 2019

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer

artículo científico publicado en 2010

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

artículo científico publicado en 2017

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer

artículo científico publicado en 2005

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

artículo científico publicado en 2013

Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma ⬇️

artículo científico publicado el 15 de marzo de 2013

Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms

artículo científico publicado en 2013

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

artículo científico publicado en 2012

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

artículo científico publicado en 2010

Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma

artículo científico publicado en 2016

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

artículo científico publicado en 2017

Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?

artículo científico publicado en 2019

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

artículo científico publicado en 2007

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

artículo científico publicado en 2016

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2012

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

artículo científico publicado en 2018

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

artículo científico publicado en 2016

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

artículo científico publicado en 2015

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Proteasome inhibitors in cancer therapy

artículo científico publicado en 2005

Proteasome inhibitors in cancer therapy.

artículo científico publicado en 2017

Proteasome inhibitors in cancer therapy: lessons from the first decade

artículo científico publicado en 2008

Proteasome inhibitors in multiple myeloma: 10 years later

artículo científico

Proteasome inhibitors in the treatment of multiple myeloma

artículo científico publicado en 2009

Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer

artículo científico publicado en 2006

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma

artículo científico publicado en 2018

RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.

artículo científico publicado en 2017

Race-dependent differences in risk, genomics and Epstein-Barr virus exposure in monoclonal gammopathies: Results of SWOG S0120

artículo científico publicado en 2020

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

artículo científico publicado en 2014

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma

artículo científico publicado en 2019

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

artículo científico publicado en 2007

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

artículo científico publicado en 2011

Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.

artículo científico publicado en 2003

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease

artículo científico publicado en 2019

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

scientific article published on 17 May 2019

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

artículo científico publicado en 2014

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2017

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

artículo científico publicado en 2005

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.

artículo científico publicado en 2009

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

artículo científico publicado en 2016

Single-stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication ⬇️

artículo científico publicado el 1 de febrero de 1991

Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses

artículo científico publicado en 2014

Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy

scientific article published on 22 March 2011

Successful pregnancy after cladribine therapy for hairy cell leukemia

artículo científico publicado en 2004

Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma

scientific article published on 11 May 2020

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

artículo científico publicado en 2008

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

artículo científico publicado en 2008

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191

scientific article published on 20 August 2018

Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik

artículo científico publicado en 2014

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

artículo científico publicado en 2015

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

artículo científico publicado en 2012

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

artículo científico publicado en 2008

Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells

artículo científico publicado en 2015

Targeting the proteasome as a therapeutic strategy against haematological malignancies

artículo científico publicado en 2006

Targeting the ubiquitin-proteasome pathway in breast cancer therapy

artículo científico publicado en 2006

The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types

scientific article published on 13 May 2020

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma

artículo científico publicado en 2017

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

artículo científico publicado en 2015

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

artículo científico publicado en 2016

The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

artículo científico publicado en 2011

The immunoproteasome as a target in hematologic malignancies

artículo científico publicado en 2012

The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1

artículo científico publicado en 2013

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

scientific article published on 06 July 2020

The proteasome and proteasome inhibitors in cancer therapy

artículo científico publicado en 2006

The proteasome as a target for cancer therapy.

artículo científico publicado en 2003

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

artículo científico

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

artículo científico publicado en 2003

The ubiquitin proteasome pathway from bench to bedside

artículo científico publicado en 2005

The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration

artículo científico publicado en 2012

Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

article

Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma

scientific article published on 05 June 2015

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

artículo científico publicado en 2016

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth

artículo científico publicado en 2015

Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking

artículo científico publicado en 2014

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study ⬇️

artículo científico publicado el 14 de mayo de 2013

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma

artículo científico publicado en 2017

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

scientific article published on 08 February 2019

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States

scientific article published on 29 May 2020

Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis

artículo científico publicado en 2015

Why proteasome inhibitors cannot ERADicate multiple myeloma

scientific article published on September 2013

p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda